Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, points to the need for improving the methodology of measurable residual disease (MRD) testing in acute lymphoblastic leukemia (ALL). Prof. Ottmann outlines the key areas of research in leukemia his laboratory has currently been focusing on. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
